by Steven R. Feldman, MD, PhD; Joel M. Gelfand, MD, MSCE; and Alice B. Gottlieb, MD, PhD
Although data are limited, outcomes for patients with psoriasis who become infected with SARS-CoV-2 seem to be driven by age and the previously ide......READ MORE
by Steven R. Feldman, MD, PhD; Joel M. Gelfand, MD, MSCE; and Alice B. Gottlieb, MD, PhD
Today, classes of biologics for moderate to severe plaque psoriasis include the tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhi......READ MORE
Patients with psoriasis are at increased risk of a number of autoimmune inflammatory disorders, including inflammatory bowel disease (IBD) and mult......READ MORE
In patients with psoriasis, a disease flare may result from a loss of response (eg, due to antidrug antibodies), increased disease activity, or adh......READ MORE
Psoriasis induced by tumor necrosis factor–α inhibitor (TNFi) therapy is a relatively uncommon side effect that may occur during the treatment of ......READ MORE
Selective inhibitors of the interleukin-23p19 (IL-23p19) subunit have emerged as highly effective therapies for patients with moderate to severe pl......READ MORE
